This strategic and externally focused role, based in Munich, Germany, involves developing and executing national access, pricing, and reimbursement strategies for Moderna's mRNA-based vaccines and emerging therapeutics. The lead will engage directly with health authorities and decision-makers to establish sustainable market access across the product lifecycle, with opportunities to utilize real-world data and generative AI tools for evidence generation and storytelling. [2, 3]
Lead the development and execution of national market access strategies for vaccines and pipeline therapeutics [2, 3],Own pricing and contracting approaches, ensuring alignment with global/regional frameworks and German policy [2, 3],Shape national HTA and reimbursement positioning, including readiness for evolving policy requirements [2, 3],Oversee national dossier development and submission processes (e.g., AMNOG/§35a SGB V), ensuring robust, evidence-based access narratives [2, 3],Serve as Moderna's lead representative to key national health institutions and payers (G-BA, RKI, GKV-SV, and STIKO) [2, 3],Shape national HTA submissions [2, 3],Develop evidence-driven payer value propositions [2, 3],Translate complex clinical and economic data into strategic outcomes [2, 3],Work cross-functionally and globally [2, 3]
Deep expertise in German access pathways and reimbursement systems [4],Proven experience engaging with national HTA and public health stakeholders [4],Strong analytical capabilities with hands-on expertise in real-world evidence analysis [4],Strong command of Germany's HTA, pricing, and claims-based systems [2, 3],Ability to translate complex clinical and economic data into strategic outcomes [2, 3]
Moderna offre un soutien complet à ses employés et à leurs familles. Bien qu'une liste spécifique d'avantages ne soit pas accessible au public, l'entreprise souligne son engagement envers le bien-être de son équipe. Les avantages comprennent des congés payés pour le bénévolat et un soutien au développement de carrière dans la communauté.
Externally facing, requiring direct interaction with health authorities and decision-makers [2, 3],Serve as Moderna's lead representative to key national health institutions and payers [2, 3]
Moderna est une société de biotechnologie pionnière dans une nouvelle classe de médicaments à base d'ARN messager (ARNm). La plateforme de l'entreprise s'appuie sur des avancées continues dans la science fondamentale et appliquée de l'ARNm, la technologie d'administration et la fabrication, et a permis le développement de produits thérapeutiques et de vaccins pour les maladies infectieuses, l'immuno-oncologie, les maladies rares, les maladies cardiovasculaires et les maladies auto-immunes.
BerryMap utilise des cookies pour fournir des fonctionnalités essentielles, analyser l'utilisation et améliorer votre expérience. Vous pouvez personnaliser vos préférences ci-dessous.